1. Home
  2. SFBS vs ORKA Comparison

SFBS vs ORKA Comparison

Compare SFBS & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

HOLD

Current Price

$82.85

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$84.33

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFBS
ORKA
Founded
2005
2004
Country
United States
United States
Employees
N/A
68
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.4B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
SFBS
ORKA
Price
$82.85
$84.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$93.00
$92.50
AVG Volume (30 Days)
233.4K
1.2M
Earning Date
04-20-2026
05-13-2026
Dividend Yield
1.94%
N/A
EPS Growth
21.63
N/A
EPS
1.52
N/A
Revenue
N/A
N/A
Revenue This Year
$32.30
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
$53.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$67.20
$10.97
52 Week High
$90.64
$91.00

Technical Indicators

Market Signals
Indicator
SFBS
ORKA
Relative Strength Index (RSI) 63.17 73.62
Support Level $82.02 $27.81
Resistance Level $83.74 $91.00
Average True Range (ATR) 1.70 4.67
MACD 0.32 2.31
Stochastic Oscillator 87.09 87.12

Price Performance

Historical Comparison
SFBS
ORKA

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: